SWIFT Certifies Fiorano ISO 20022 Accelerator for Cross-Border Payments and Reporting
1.7.2020 11:00:00 EEST | Business Wire | Press release
Fiorano Software, a leading provider of enterprise integration middleware, API management and banking solutions, today announced confirmation by the Society for Worldwide Interbank Financial Telecommunications (SWIFT) of Fiorano’s support for SWIFT’s Cross-Border Payments and Reporting Plus (CBPR+) message specifications. Fiorano is now one of a select set of worldwide vendors whose solution has cleared certification requirements by SWIFT for CBPR+ readiness.
Fiorano also recently announced the availability of a SWIFT-Confirm pack to confirm payments, corresponding to the November 2020 “universal confirmations” deadline, through SWIFT-approved automated routes including MT 199, API calls and CSV batches with an easy upgrade path to SWIFT gpi and SWIFT CBPR+ / ISO 20022.
“Being able to deliver out-of-the-box support for SWIFT Universal Confirmations and CBPR+ as an overlay service is critical for Banks and Financial Institutions looking to meet immediate SWIFT and broader ISO 20022 requirements without upgrading existing backend systems,” said Biju Suresh Babu, Managing Director – Banking and Financial Services, Fiorano Software. “Fiorano has been steadily adding functionality and features aimed at helping customers and partners deliver ISO 20022 compliance in line with SWIFT and broad global payment scheme support with minimal impact and disruption,” he added.
Built on the proven enterprise-class, secure and scalable Fiorano Hybrid Integration Platform (HIP), coupled with a powerful set of ISO 20022-ready adapters, the Fiorano ISO 20022 Accelerator enables rapid adoption of the ISO 20022 messaging standard through connectors and tools that facilitate code-less implementations for rapid readiness.
About Fiorano : Fiorano Software, a Silicon Valley based Corporation, is a trusted provider of hybrid integration and API technology, enabling interoperability, profitability and new revenue streams, since 1995. Fiorano operates through its worldwide offices and a global network of technology partners and value-added resellers. Global companies including AT&T Wireless, Federal Bank, NASA, Bank of Kigali, Commercial Bank of Africa, Canadia Bank, US Coast Guard and Vodafone have deployed Fiorano to drive innovation through open, standards-based, event-driven, real-time solutions yielding unprecedented productivity.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005364/en/
Contact information
Sumit Kuhite
+1 650 326 1136
mediarelations@fiorano.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu ® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from theDESTINY-Breast09 phase 3 trialpresented at the 2025 American Society of Clinical Oncology Annual Meeting and subsequently published in The New England Journal of Medicine. In DESTINY-Breast09, Enhertu in combination with pertuzumab reduced the risk of disease progression or death by 44% versus a taxan
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 09:30:00 EEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
ADM Club Digitises the Renaissance Court Model Through a Bespoke Technology Stack for Independent Luxury and High Affinity Audiences1.9.2026 09:08:00 EEST | Press release
Alessia Demetz, Founder & CEO of Alesya de Monaco LTD, headquartered in London and the Principality of Monaco, created ADM Club – a business model built on a vertical digital architecture and designed for global scalability – operating at the intersection of luxury craftsmanship and an international network of high-net-worth connoisseurs. This powerful, disruptive vision — bringing hyper-curated craft direct to the customer — translates into digital form the role once played by patrons within Renaissance courts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260821319838/en/ Credits: Photo courtesy of ADM Club. Photography by Martin Morrell. Designed from the outset to enable the model to scale, this architecture supports both the development of the ADM Club network and deployment with international partners, opening the way to collaborations with operators and organisations that reach high-spending audiences. ADM Club is no
Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 09:00:00 EEST | Press release
Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize critical infrastructure, this partnership provides a scalable and reliable framework for implementing intelligent street lighting systems that reduce ener
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom